Anavex Life Sciences Corp (AVXL)

[samk]

it2211, yes the are a couple of potential catalysts:

- partnership

- start of P2/P3.


as P3 will progress and interim results are good,

AVXL might get a nod from FDA by being awarded FTD, BTD or accelerated approval.

We have to remember, that the trials so far had a goal to find the optimum dose for P3 and they achieved the goal. The patients that responded to optimal dose showed substantial improvement, but did not have statistical value. P3 might change all this.

I think as long as AVXL has a potential to report excellent results in P3, it has potential as an investment.

Even if P3 results will be just better than current standard treatment, AVNX has a big chance with its excellent safety profile, IMO.